| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director
1 company
Jacqueline Northcut last filed a Form 4 in May 2017, as Director at MBRX. Jacqueline Northcut's net worth is not public. Form 4 filings only show shares in the companies where this person was an insider, as of the last filing.
At the last filing, the largest reported position was 1,000 shares of MBRX. Net of sales, the MBRX filings show accumulation of 1,000 shares.
Jacqueline Northcut has 2 Form 4 filings on record from September 2016 to May 2017, all as Director at Moleculin Biotech (MBRX), 2016–2017.
The 2 reported transactions were 1 open-market purchase and 1 option or other derivative award.
Counted by filing, the open-market trades come to 1 purchase worth about $820 and no sales.
The only open-market purchase was 1,000 shares of MBRX at an average $0.82 on May 5, 2017, about $820.
Shares as reported in the last Form 4 for each company; the most recent is from May 2017. Values use today's prices. Any trades after the last filing were not reported, so current holdings may differ.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|
| May 5, 2017 | MBRX Moleculin Biotech, Inc. | Director | Buy | 1,000 | $0.82 | $820.00 | New |